- |||||||||| Ninlaro (ixazomib) / Takeda
Machine learning (Hall A - Posters and Exhibits; Poster Bd #: 93) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2932; PFS models demonstrated improved performance by incorporating predicted ETR risk as an additional feature. The ETR-incorporated models with clinical and genetic data stratified patients into low-and high-risk groups proposing optimal treatment strategies to potentially improve PFS in 185 patients (35%).
- |||||||||| Blenrep (belantamab mafodotin-blmf) / GSK
Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials. (Hall A - Posters and Exhibits; Poster Bd #: 116) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2919; P1, P3 In pts with mild/moderate renal impairment, belamaf-containing regimens (BVd and BPd) showed improved efficacy vs standard triplets, indicating they are an efficacious alternative SOC in a broad range of pts with RRMM. Safety results in this pt population were consistent with the ITT populations.
- |||||||||| Talvey (talquetamab-tgvs) / J&J
Prophylactic interventions for oral toxicities with the GPRC5D (Hall A - Posters and Exhibits; Poster Bd #: 132a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2916; P2 Key secondary endpoints include changes from baseline in WETT score, body weight, and smell identification and smell detection threshold test scores over time; characterization of the safety and efficacy of Tal; change from baseline in PRO (including impacts of oral toxicities) assessments; and frequency of dose modifications. Enrollment opened in August 2024 for these 4 cohorts and target enrollment is 70
- |||||||||| Elrexfio (elranatamab-bcmm) / Pfizer
MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38 (Hall A - Posters and Exhibits; Poster Bd #: 133b) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2904; P3 Clinical trial information: NCT02659293. This study will evaluate ELRA monotherapy vs elotuzumab-pomalidomide-dexamethasone (EPd), pomalidomide-bortezomib-dexamethasone (PVd), or carfilzomib-dexamethasone (Kd) in patients with RRMM to determine whether ELRA can provide superior clinical benefit in early relapse (2L+)...Key inclusion criteria include age of ?18 years, prior multiple myeloma diagnosis with measurable disease (per IMWG criteria), evidence of progressive disease or failure to achieve a response to last line of multiple myeloma therapy, 1 to 4 prior lines of therapy including an anti
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment closed, Trial completion date, Trial primary completion date: Isa-Pom-Dex in Elderly/Frail Subjects With RRMM (clinicaltrials.gov) - Apr 22, 2025 P2, N=6, Active, not recruiting, Recruiting --> Active, not recruiting Suspended --> Active, not recruiting | Trial completion date: Mar 2031 --> Mar 2028 | Trial primary completion date: Dec 2028 --> Jun 2025
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Trial completion, Trial completion date: 12-C-0107: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2025 P2, N=55, Completed, N=482 --> 28 | Trial completion date: Mar 2033 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2028 --> Mar 2025; The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient. Active, not recruiting --> Completed | Trial completion date: Jun 2028 --> Feb 2025
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
Journal: MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study. (Pubmed Central) - Apr 21, 2025 These findings also highlight the potential utility of miRNAs in liquid biopsies as a predictive tool of drug response in MM and could pave the way for personalized treatment strategies, improving patient outcomes. Future research is needed to validate these results in larger cohorts and explore the underlying mechanisms of miR-665 in MM pathogenesis and drug resistance.
- |||||||||| cabergoline / Generic mfg., hydrocortisone / Generic mfg.
Journal: Pituitary Complications of Enchondromas Due to Maffucci Syndrome. (Pubmed Central) - Apr 21, 2025 With hormonal treatments including thyroid hormone replacement, hydrocortisone, and cabergoline, the patient's symptoms of fatigue and cold intolerance improved. We highlight the importance of endocrinological evaluation in patients with neurological tumors related to MS.
- |||||||||| hydroxychloroquine / Generic mfg., prednisolone / Generic mfg., methotrexate / Generic mfg.
Journal: Normal tension glaucoma as initial manifestation of Takayasu arteritis- an unknown entity. (Pubmed Central) - Apr 21, 2025 This case highlights the importance of tailored therapy, particularly in rare diseases. This case highlights the importance of comprehensive ophthalmic evaluation in patients with NTG and the need to consider systemic conditions, such as TA, as potential underlying cause in young female patients presenting with NTG.
|